Recent studies have indicated that the HMGB1 level is increased in NAFLD in both animals11, 12, 13 and the clinic14, 15 and that HMGB1 inhibition results in a significant reduction in the inflammatory response in NAFLD9, 16. Here, HMGB1 is linked to metabolic dysfunction-associated steatotic liver disease.